Innovation Pharmaceuticals Inc (IPIX)

[wsbc]

My feeling is that we need both.

IV and aerosol in the instance of CV-related cases would be critical-care team administered and monitored... this is an ICU situation, not as someone else mentioned, a tennis-court scenario in the hands of the 'random public'.

A respiratory professional should be well-enough equipped to monitor dosing.

A point of note: Trump is not a medical professional. He's not even really a 'business professional' with any capability. I remain unconvinced that anything he says in this situation related to accurate numbers/info about much of anything, can be taken seriously.

On the ground here (I'm in Colorado) much of the critical management concerns are being handled locally and regionally. We have little/no federal assistance, so local hospitals are fending for themselves. So far nothing that 'Trump has done' has meant anything to our situation (or others I'm aware of).

Maybe and I get that assumptive method of dosing just don't have enough personal experience with inhalers myself but just thinking out loud that it may be tough for an acute sufferer with CV to get a full breathe in and just think IV dose would be faster to market than inhaler. Once/IF FDA give the go ahead for controlled trial I would think speed is of the essence for millions of doses. (Taking that based on Trump saying HCQ has millions of doses ordered)